Topical gentian violet compared with nystatin oral suspension for the treatment of oropharyngeal candidiasis in HIV-1-infected participants.

ABSTRACT:

Objective

Compare the safety and efficacy of topical gentian violet with that of nystatin oral suspension (NYS) for the treatment of oropharyngeal candidiasis in HIV-1-infected adults in resource-limited settings.

Design

Multicenter, open-label, evaluator-blinded, randomized clinical trial at eight international sites, within the AIDS Clinical Trials Group.

Study participants and intervention

Adult HIV-infected participants with oropharyngeal candidiasis, stratified by CD4 cell counts and antiretroviral therapy status at study entry, were randomized to receive either gentian violet (0.00165%, BID) or NYS (500 000 units, QID) for 14 days.

Main outcome measure(s)

Cure or improvement after 14 days of treatment. Signs and symptoms of oropharyngeal candidiasis were

SUBMITTER: Mukherjee PK 

PROVIDER: S-EPMC5127761 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature